Influence of urethane and ketamine on rat hepatic cytochrome P450 in vivo

Experimental and Toxicologic Pathology

Volumn 51, Issue 4-5, 1999, Pages 392-396

  Meneguz, Annarita ^a   Fortuna, Stefano ^a   Lorenzini, Paola ^a   Volpe, Maria Teresa ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

7 ethoxyresorufin; 7 Pentoxyresorufin; Aniline; Cytochrome P 450; Cytochrome P 450; Ethylmorphine; Hepatic; Ketamine; Liver; Urethane

Indexed keywords

ANILINE; CYTOCHROME P450; ETHOXYRESORUFIN; ETHOXYRESORUFIN DEETHYLASE; ETHYLMORPHINE; KETAMINE; LIVER ENZYME; PENTOXYRESORUFIN; PENTOXYRESORUFIN DEALKYLASE; RESORUFIN; URETHAN;

ANIMAL EXPERIMENT; CHEMICAL MODIFICATION; CONFERENCE PAPER; CONTROLLED STUDY; DEMETHYLATION; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENERAL ANESTHESIA; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER METABOLISM; MALE; NONHUMAN; RAT;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0032780945     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(99)80027-X     Document Type: Conference Paper

References (34)

1. BACHMANN KA, SANYAL G, POTTER J, et al.: In vivo evidence that theophylline is metabolized principally by CYP 1A in rats. Pharmacology 1993; 47: 1-7.
2. BARNETT CR, RUDD S, FLATT PR, IOANNIDES C: Sex differences in the diabetes-induced modulation of rat hepatic cytochrome P450 proteins. Biochem Pharmacol 1993; 45: 313-319.
3. BARTUS RT, BAKER KL, HEISER AD, et al.: Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J Cerebral Blood Flow Metab 1994; 14: 537-544.
4. BONDY SC, NADERI S: Contribution of hepatic cytochrome P450 systems to the generation of reactive oxygen species. Biochem Pharmacol 1994; 48: 155-159.
5. BRADY JF, LEE MJ, LI M, et al.: Diethyl ether as a substrate for acetone/ethanol-inducible cytochrome P450 and as an inducer for cytochrome(s) P450. Mol Pharmacol 1987; 33: 148-154.
6. BROWN BR: Enzymatic activity and biotransformation of anesthetics. Int Anesthesiol Clin 1974; 12: 25-34.
7. BURKE M, MAYER RT: Ethoxyresorufin: direct fluorimetric assay of microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab Dispos 1974; 2: 583-590.
8. CHUNG SJ, RAMANATHAN VK, BRETT CM, GIACOMINI KM: Saturable disposition of taurine in the rat cerebrospinal fluid. J Pharmacol Exp Ther 1996; 276: 676-682.
9. CIACCIO PJ, HALPERT JR: Characterization of a phenobarbital-inducible dog liver cytochrome P450 structurally related to rat and human enzymes of the P450 III A (steroid-inducible) gene subfamily. Arch Biochem Biophys 1989; 271: 284-299.
10. ECA T, WELLS PG: Biochemical changes associated with the potentiation of acetaminophen hepatotoxicity by brief anaesthesia with diethyl ether. Biochem Pharmacol 1986; 35: 4139-4152.
11. FEE JPH, DUNDEE JW, CLARKE RSJ, BOVIL JG: Volatile inhalation anesthetics, nonbarbiturate intravenous anaesthetics, and opioids; in DUNDEE JW, CLARKE RSJ, MCCAUGHEY WM (eds): Clinical Anaesthetic Pharmacology. Edinburg Churchill Livingstone. 1991; pp. 116-118, 170, 216-219.
12. GLAZER RI, CINTI DL, MURAHATA RI, et al.: Metabolic action of urethan on protein synthesis and drug oxidation in normal and regenerating liver. Biochemical Pharmacol 1972; 21: 2867-2875.
13. GONZALES F: The molecular biology of cytochrome P450s. Pharmacol Rev 1989; 40: 244-288.
14. GUENGERICH FP: In Frontiers of Biotransformations (RUCKPAUL K and REIN H, eds), vol 1, Taylor and Francis, London, 1989, pp. 101-150.
15. INGELMAN-SUNDBERG M, JOHANSSON I, YIN H, et al.: Ethanol-inducible cytochrome P450 2E1: genetic polymorphism, regulation, and possible role in the ethiology of alcohol-induced liver disease. Alcohol 1993; 10: 447-452.
16. IOANNIDES C, PARKE DV: Induction of cytochrome P450 1 as an indicator of potential chemical carcinogenesis. Drug Metab Rev 1993; 25: 485-501.
17. KIM ND, KWAK MK, KIM SG: Inhibition of cytochrome P450 2E1 expression by 2-(allylthio) pyrazine, a potential chemoprotective agent: hepatoprotective effects. Biochem Pharmacol 1997; 53: 261-269.
18. KURATA N, HURST HE, BENZ FW, et al.: Studies on inhibition and induction of methabolism of ethyl carbamate by acetone and related compounds. Drug Metab Disp 1991; 19: 388-393.
19. LABELLA FS, QUEEN G: General anesthetics inhibit cytochrome P450 monooxygenases and arachidonic acid metabolism. Can J Physiol Pharmacol 1992; 71: 48-53.
20. LIU PT, IOANNIDES C, SHAVILA J, et al.: Effects of ether anaesthesia and fasting on various cytochromes P450 of rat liver and kidney. Biochem Pharmacol 1993; 45: 871-877.
21. LOCH JM, POTTER J, BACHMANN KA: The influence of anesthetic agents on rat hepatic cytochromes P450 in vivo. Pharmacology 1995; 50: 146-153.
22. LUBERT RA, MAYER RT, CAMERON JW, et al.: Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P450 by phenobarbital and other xenobiotics in the rat. Arch Bioche Biophys 1985; 238: 43-48.
23. MARIETTA MP, WHITE PF, PUDWILL CR, et al.: Biodisposition of ketamine in the rat: self-induction of metabolism. J Pharmacol Exp Ther 1975; 196: 536-544.
24. MAZEL P: Experiments illustrating drug metabolism in vitro. In: LA DU BN, MANDEL HG, WAY EL (eds): Fundamentals of drug Metabolism and Disposition. Williams and Wilkins, Baltimore. 1972; p. 546.
25. MENEGUZ A, MICHALEK H: Effect of Diisopropyl Fluorophosphate on hepatic microsomal systems in two strain of rats. Bull Environ Contam Toxicol 1990; 44: 924-931.
26. NELSON DR, KAMATAKI T, WAXMAN DJ, et al.: The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol 1993; 12: 1-51.
27. NOMEIR AA, IOANNOU YM, SANDERS JM, MATTHEWS HB: Comparative metabolism and disposition of ethyl carbamate (urethane) in male fischer 344 rats and male B6C3F1 mice. Toxicol Appl Pharmacol 1989; 97: 203-215.
28. OMURA T, SATO R: The carbon monoxide pigment of liver microsomes I Evidence for its haemoprotein nature. J Biol Chem 1964; 239: 2370-2378.
29. RYAN DE, LEWIN W: Purification and characterization of hepatic cytochrome P450. Pharmacol Ther 1990; 45: 153-239.
30. SMITH DA: Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metab Rev 1991; 23: 355-373.
31. SORRENTI V, DI GIACOMO C, RENIS M, et al.: Lipid peroxidation and survival in rats following cerebral postischaemic reperfusion: effect of drugs with different molecular mechanisms. Drugs Exp Clin Res 1994; XX (5): 185-189.
32. 2++ antagonist drugs. Int J Devl Neurosci 1992; 10: 75-80.
33. WAXMAN DJ, AZAROFF L: Phenobarbital induction of cytochrome P450 gene expression Biochem J 1992; 281: 577-592.
34. YAMAMOTO T, PIERCE Jr WM, HURST HE, et al.: Ethyl carbamate metabolism: in vivo and in vitro enzymatic systems. Drug Metab Disp 1990; 18: 276-280.